Bank of Nova Scotia’s Catalyst Pharmaceutical CPRX Stock Holding History

Bank of Nova Scotia’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-15,248	Closed	-$196K	–	1183
2022 Q3	$196K	Buy	+15,248	New	+$181K	﹤0.01%	1099

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bank of Nova Scotia's CPRX Position: Q4 2022 in Review

Bank of Nova Scotia sold out of Catalyst Pharmaceutical (CPRX) in Q4 2022, closing a stake of 15,248 shares — an estimated $196K sold.

Bank of Nova Scotia first reported a position in CPRX in Q3 2022 and held it in 1 quarter. The position peaked at $196K in Q3 2022. 257 funds tracked by Wall St. Rank hold CPRX as of Q4 2022.

Bank of Nova Scotia reported no remaining Catalyst Pharmaceutical position as of Q4 2022 after selling out during the quarter.
Bank of Nova Scotia sold 15,248 Catalyst Pharmaceutical shares in Q4 2022, an estimated $196K.
Bank of Nova Scotia first reported a position in Catalyst Pharmaceutical in Q3 2022 and held it in 1 quarter.
Bank of Nova Scotia's Catalyst Pharmaceutical position peaked at $196K in Q3 2022.
257 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2022.

Based on Bank of Nova Scotia's 13F filing for Q4 2022, filed 9 Feb 2023.